TMCI
Treace Medical Concepts, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-9/100
Last price
4.00
▼ 0.48 (10.71%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.90
Prev close
4.48
Day high
4.53
Day low
3.98
Volume
652.04K
Market cap
$260.14M
P/E (TTM)
—
52W range
1.17 – 7.08
Day trading desk
Gap from prior close
+9.37%
Prior close 4.48
VWAP
4.14
-3.38% from price
Relative volume
1.93×
Unusually busy
Session range
23.12%
3.98 – 4.90
Position in range
2%
Near session low
ATR (14D)
0.23
5.72% of price
Prior day high
4.54
PDH
Prior day low
4.24
PDL
Bid / ask spread
—
Quote not published
Session volume
641.91K
Avg 333.45K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-13.42%
-15.4%
1M
-16.84%
-18.0%
3M
-6.54%
-11.1%
6M
+198.51%
+180.3%
YTD
+63.27%
+49.0%
1Y
-37.11%
-53.5%
3Y
-69.49%
-151.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TMCI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
16.41M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 24, 26 | TREACE JOHN T. Chief Executive Officer |
BUY | 55.94K | $246.65K | Direct |
| Jun 11, 26 | TREACE JOHN T. Chief Executive Officer |
BUY | 52.32K | $210.97K | Direct |
| Jun 11, 26 | TREACE JOHN T. Chief Executive Officer |
BUY | 24.61K | $99.20K | Direct |
| Jun 1, 26 | TREACE JOHN T. Chief Executive Officer |
BUY | 50.00K | $177.91K | Direct |
| May 28, 26 | TREACE JOHN T. Chief Executive Officer |
BUY | 115.52K | $340.59K | Direct |
| May 19, 26 | HAMILTON LAWRENCE W Director |
STOCK | 30.00K | $0 | Direct |
| May 19, 26 | BAKEWELL JOHN K Director |
STOCK | 30.00K | $0 | Direct |
| May 19, 26 | BERRY LANCE A Director |
STOCK | 30.00K | $0 | Direct |
| May 19, 26 | JAIN DEEPTI Director |
STOCK | 30.00K | $0 | Direct |
| May 19, 26 | HANNA BETSY Director |
STOCK | 30.00K | $0 | Direct |
| May 19, 26 | KIERNAN JANE E. Director |
STOCK | 30.00K | $0 | Direct |
| May 14, 26 | TREACE JOHN T. Chief Executive Officer |
BUY | 153.76K | $375.50K | Direct |
| Apr 1, 26 | HAIR MARK Chief Financial Officer |
STOCK | 100.00K | $0 | Direct |
| Feb 10, 26 | SCANLAN SEAN F Officer |
CONVERSION | 16.88K | $17.72K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKEWELL JOHN K |
Director | 546.36K | Stock Award(Grant) |
BERUTTI AARON |
Officer | 212.54K | Stock Award(Grant) |
ELDER SCOT MICHAEL |
Officer | 796.79K | Stock Award(Grant) |
GUGLIELMINO GAETANO |
Officer | 490.90K | Stock Award(Grant) |
GUGLIELMINO GUY |
Officer | 363.00K | Stock Award(Grant) |
HAIR MARK |
Chief Financial Officer | 963.55K | Stock Award(Grant) |
JAIN DEEPTI |
Director | 100.24K | Stock Award(Grant) |
MOTT RICHARD W |
Director | 1.10M | Stock Award(Grant) |
SCANLAN SEAN F |
Officer | 706.47K | Conversion of Exercise of derivative security |
TREACE JOHN T. |
Chief Executive Officer | 12.73M | Purchase |
Fundamentals
Market cap$260.14M
Enterprise value$287.57M
Revenue (TTM)$205.31M
Gross profit$163.12M
EBITDA$-46.35M
Net income$-59.52M
EPS (TTM)$-0.92
Free cash flow$-6.25M
Total cash$45.62M
Total debt$73.05M
Book value / share$1.04
Shares outstanding65.03M
Float47.80M
Short % of float3.35%
Dividend yield0.00%
Beta (5Y)1.49
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.71
PEG ratio—
Price / sales—
Price / book3.84
EV / revenue1.40
EV / EBITDA-6.20
Gross margin79.45%
Operating margin-32.97%
Profit margin-28.99%
Return on equity-71.99%
Return on assets-17.33%
Debt / equity107.84
Current ratio2.90
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $212.69M | $209.36M | $187.12M | $141.84M | +1.6% |
| Operating revenue | $212.69M | $209.36M | $187.12M | $141.84M | +1.6% |
| Cost of revenue | $42.94M | $41.09M | $35.18M | $25.53M | +4.5% |
| Gross profit | $169.75M | $168.26M | $151.94M | $116.31M | +0.9% |
| Research & development | $20.28M | $20.59M | $15.44M | $13.58M | -1.5% |
| Selling, general & admin | $203.62M | $203.36M | $187.93M | $137.57M | +0.1% |
| Total operating expense | $223.91M | $223.95M | $203.37M | $151.15M | -0.0% |
| Operating income | -$54.15M | -$55.69M | -$51.43M | -$34.84M | +2.8% |
| Net interest income | -$2.54M | -$379.00K | $1.56M | -$3.08M | -571.0% |
| Pre-tax income | -$59.00M | -$55.74M | -$49.53M | -$42.81M | -5.8% |
| Net income | -$59.00M | -$55.74M | -$49.53M | -$42.81M | -5.8% |
| Net income to common | -$59.00M | -$55.74M | -$49.53M | -$42.81M | -5.8% |
| Basic EPS | -0.93 | -0.90 | -0.81 | -0.77 | -3.3% |
| Diluted EPS | -0.93 | -0.90 | -0.81 | -0.77 | -3.3% |
| EBIT | -$53.68M | -$50.49M | -$44.36M | -$38.42M | -6.3% |
| EBITDA | -$43.06M | -$42.07M | -$39.01M | -$36.28M | -2.4% |
| Basic shares | 63.27M | 62.11M | 60.85M | 55.28M | +1.9% |
| Diluted shares | 63.27M | 62.11M | 60.85M | 55.28M | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $10.71M | $11.35M | $12.98M | $19.47M | -5.7% |
| Cash & short-term investments | $48.37M | $75.68M | $123.20M | $81.25M | -36.1% |
| Accounts receivable | $42.16M | $40.80M | $38.06M | $29.20M | +3.3% |
| Inventory | $36.03M | $39.26M | $29.25M | $19.33M | -8.2% |
| Total current assets | $132.05M | $161.40M | $198.36M | $133.40M | -18.2% |
| Property, plant & equipment | $37.37M | $34.40M | $31.56M | $25.48M | +8.6% |
| Goodwill & intangibles | $19.94M | $20.89M | $21.84M | $0 | -4.5% |
| Total assets | $190.58M | $217.09M | $251.91M | $159.02M | -12.2% |
| Total current liabilities | $30.64M | $34.92M | $45.03M | $30.25M | -12.3% |
| Current debt | $1.75M | — | — | — | — |
| Long-term debt | $55.58M | $53.31M | $53.01M | $52.71M | +4.3% |
| Total debt | $71.86M | $69.65M | $70.30M | $68.59M | +3.2% |
| Total liabilities | $103.25M | $104.20M | $113.97M | $98.50M | -0.9% |
| Retained earnings | -$248.99M | -$189.99M | -$134.25M | -$84.72M | -31.1% |
| Shareholder equity | $87.33M | $112.89M | $137.94M | $60.53M | -22.6% |
| Working capital | $101.42M | $126.48M | $153.33M | $103.16M | -19.8% |
| Net tangible assets | $67.39M | $92.00M | $116.10M | $60.53M | -26.7% |
| Shares issued | 64.03M | 62.39M | 61.75M | 55.63M | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$59.00M | -$55.74M | -$49.53M | -$42.81M | -5.8% |
| Depreciation & amortisation | $10.62M | $8.42M | $5.35M | $2.13M | +26.2% |
| Stock-based compensation | $33.82M | $30.60M | $17.35M | $8.11M | +10.5% |
| Change in working capital | -$8.58M | -$25.43M | -$9.74M | -$5.81M | +66.2% |
| Operating cash flow | -$15.97M | -$37.17M | -$34.58M | -$30.65M | +57.0% |
| Capital expenditure | -$13.52M | -$11.59M | -$11.46M | -$14.84M | -16.6% |
| Investing cash flow | $13.25M | $35.38M | -$81.30M | -$76.52M | -62.5% |
| Dividends paid | $0 | $0 | $0 | — | — |
| Financing cash flow | $2.08M | $160.00K | $109.38M | $20.81M | +1,198.1% |
| Free cash flow | -$29.49M | -$48.76M | -$46.03M | -$45.49M | +39.5% |
| End cash position | $10.71M | $11.35M | $12.98M | $19.47M | -5.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $45.38M | $47.20M | $62.52M | $50.21M | $47.39M | -3.9% |
| Operating revenue | $45.38M | $47.20M | $62.52M | $50.21M | $47.39M | -3.9% |
| Cost of revenue | $9.77M | $9.79M | $12.12M | $10.51M | $9.63M | -0.2% |
| Gross profit | $35.61M | $37.41M | $50.40M | $39.71M | $37.75M | -4.8% |
| Research & development | $4.38M | $4.62M | $4.54M | $4.68M | $5.50M | -5.3% |
| Selling, general & admin | $46.19M | $49.95M | $51.78M | $50.70M | $49.23M | -7.5% |
| Total operating expense | $50.56M | $54.57M | $56.32M | $55.38M | $54.73M | -7.3% |
| Operating income | -$14.96M | -$17.17M | -$5.92M | -$15.68M | -$16.97M | +12.9% |
| Net interest income | -$1.12M | -$1.07M | -$823.00K | -$704.00K | -$546.00K | -4.5% |
| Pre-tax income | -$15.87M | -$17.96M | -$9.39M | -$16.29M | -$17.40M | +11.6% |
| Net income | -$15.87M | -$17.96M | -$9.39M | -$16.29M | -$17.40M | +11.6% |
| Net income to common | -$15.87M | -$17.96M | -$9.39M | -$16.29M | -$17.40M | +11.6% |
| Basic EPS | -0.24 | -0.28 | -0.15 | -0.26 | -0.28 | +14.3% |
| Diluted EPS | -0.24 | -0.28 | -0.15 | -0.26 | -0.28 | +14.3% |
| EBIT | -$14.31M | -$16.39M | -$8.04M | -$14.95M | -$16.08M | +12.7% |
| EBITDA | -$12.42M | -$15.49M | -$5.24M | -$12.17M | -$13.50M | +19.8% |
| Basic shares | 65.05M | 64.59M | 63.86M | 63.52M | 63.01M | +0.7% |
| Diluted shares | 65.05M | 64.59M | 63.86M | 63.52M | 63.01M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.61M | $9.54M | $10.71M | $7.69M | $8.05M | +32.1% |
| Cash & short-term investments | $45.62M | $51.85M | $48.37M | $57.42M | $69.29M | -12.0% |
| Accounts receivable | $28.73M | $30.36M | $42.16M | $32.96M | $30.33M | -5.4% |
| Inventory | $39.54M | $36.37M | $36.03M | $41.42M | $42.40M | +8.7% |
| Total current assets | $120.45M | $123.47M | $132.05M | $138.00M | $147.60M | -2.4% |
| Property, plant & equipment | $39.63M | $39.43M | $37.37M | $37.80M | $37.75M | +0.5% |
| Goodwill & intangibles | $19.46M | $19.70M | $19.94M | $20.18M | $20.41M | -1.2% |
| Total assets | $181.06M | $184.10M | $190.58M | $196.59M | $206.44M | -1.7% |
| Total current liabilities | $41.50M | $34.49M | $30.64M | $40.91M | $41.90M | +20.3% |
| Current debt | $3.17M | $1.78M | $1.75M | $1.80M | $1.11M | +78.4% |
| Long-term debt | $56.04M | $55.82M | $55.58M | $53.53M | $53.45M | +0.4% |
| Total debt | $72.69M | $71.60M | $71.86M | $70.37M | $70.09M | +1.5% |
| Total liabilities | $113.32M | $106.91M | $103.25M | $107.40M | $108.83M | +6.0% |
| Retained earnings | -$282.83M | -$266.95M | -$248.99M | -$239.60M | -$223.31M | -5.9% |
| Shareholder equity | $67.74M | $77.19M | $87.33M | $89.19M | $97.61M | -12.2% |
| Working capital | $78.96M | $88.98M | $101.42M | $97.09M | $105.70M | -11.3% |
| Net tangible assets | $48.27M | $57.49M | $67.39M | $69.01M | $77.20M | -16.0% |
| Shares issued | 64.98M | 65.03M | 64.03M | 63.85M | 63.12M | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.87M | -$17.96M | -$9.39M | -$16.29M | -$17.40M | +11.6% |
| Depreciation & amortisation | $1.89M | $899.00K | $2.81M | $2.78M | $2.58M | +110.0% |
| Stock-based compensation | $6.46M | $8.03M | $7.55M | $8.00M | $9.58M | -19.6% |
| Change in working capital | $1.12M | $14.73M | -$13.11M | -$4.67M | $1.49M | -92.4% |
| Operating cash flow | -$4.70M | $7.24M | -$8.03M | -$9.09M | -$3.05M | -164.9% |
| Capital expenditure | -$2.20M | -$3.06M | -$2.40M | -$2.81M | -$4.77M | +28.1% |
| Investing cash flow | $7.07M | -$7.82M | $9.67M | $8.74M | -$3.26M | +190.4% |
| Financing cash flow | $696.00K | -$588.00K | $1.38M | -$10.00K | $987.00K | +218.4% |
| Free cash flow | -$6.90M | $4.18M | -$10.42M | -$11.90M | -$7.82M | -265.1% |
| End cash position | $12.61M | $9.54M | $10.71M | $7.69M | $8.05M | +32.1% |
Options analytics
Put / call volume
0.10
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-37.5% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
10
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.30 | -0.20 | +33.3% |
| Mar 2026 | -0.31 | -0.12 | +62.8% |
| Dec 2025 | -0.14 | -0.08 | +44.1% |
| Sep 2025 | -0.27 | -0.22 | +18.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.25 | 1 | $47.71M | -5.0% |
| Next quarter | -0.11 | 1 | $67.30M | +7.6% |
| Current year | -0.85 | 5 | $207.47M | -2.5% |
| Next year | -0.85 | 1 | $221.73M | +6.9% |
Analyst targets & ownership
Mean target$5.50
High target$7.00
Low target$4.50
Implied upside37.50%
Analyst count3
ConsensusNONE
Strong buy / Buy0 / 1
Hold3
Sell / Strong sell0 / 1
Held by insiders25.24%
Held by institutions49.68%
Institutions holding151
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.43
-9.69% from price
SMA 20
4.48
-10.65% from price
SMA 50
4.54
-11.84% from price
SMA 100
4.19
-4.54% from price
SMA 200
3.09
+29.37% from price
EMA 12
4.41
-9.25% from price
EMA 26
4.47
-10.59% from price
EMA 50
4.42
-9.40% from price
RSI (14)
35.3
Neutral
MACD (12,26,9)
-0.07
Hist -0.04
ATR (14)
0.23
5.72% of price
Realised vol 30D
55.2%
Annualised
Bollinger upper
4.75
20, 2σ
Bollinger lower
4.21
20, 2σ
50 / 200 cross
Golden
4.54 vs 3.09
Trend bias
Above 200
+29.37%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.55
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
55.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-82.7%
Peak to trough
Max drawdown 5Y
-95.7%
Peak to trough
ATR 14
0.23
5.72% of price
Beta (reported)
1.49
5Y monthly, from filing
Short interest
Shares short
1.74M
Prior 1.60M
Change vs prior
+8.8%
Shorts adding
% of float
3.35%
Normal
% of shares out
2.67%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
47.80M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Jul 16, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Mar 2, 26 | Lake Street | MAINTAINED | Buy | Buy |
| Jan 7, 26 | Stifel | MAINTAINED | Hold | Hold |
| Dec 18, 25 | Truist Securities | MAINTAINED | Hold | Hold |
| Nov 10, 25 | Truist Securities | MAINTAINED | Hold | Hold |
| Nov 7, 25 | UBS | MAINTAINED | Neutral | Neutral |
| Nov 7, 25 | JP Morgan | DOWNGRADE | Neutral | Underweight |
| Nov 7, 25 | BTIG | DOWNGRADE | Buy | Neutral |
| Oct 15, 25 | Truist Securities | MAINTAINED | Hold | Hold |
| Sep 4, 25 | Truist Securities | MAINTAINED | Hold | Hold |
| Aug 8, 25 | UBS | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-05-20
Corporate Changes & Voting Matters
8-K · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-04-09
Annual Report to Shareholders
ARS · 2026-04-06
Corporate Changes & Voting Matters
8-K · 2026-02-27
Corporate Changes & Voting Matters
8-K · 2026-01-13
Corporate Changes & Voting Matters
8-K · 2025-12-18
Headlines
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
Insider Monkey · 14d ago
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
GlobeNewswire · 19d ago
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Zacks · 20d ago
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
GlobeNewswire · 21d ago
Treace Medical (TMCI) Q2 2026 Earnings Call Transcript
Motley Fool · 54d ago
Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating
MT Newswires · 58d ago
Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary
Moby · 60d ago
Treace Medical Concepts Inc (TMCI) (Q2 2026) Earnings Call Highlights: Revenue Declines 4% but ...
GuruFocus.com · 60d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.